The Fed decision hits Wednesday afternoon. Futures are already pricing in a move.

That's the macro story everyone's talking about, but underneath it this week is loaded with dividend actions worth your attention: an HR services company every small business feels, the country's biggest renewables utility, and a Pentagon supplier you probably don't own.

Let's get into it.

Only a tiny percentage of stocks meet the criteria for this report.

Analysts have released a new edition highlighting seven names selected using multiple indicators.

Recent picks have delivered notable short-term gains, though results can vary.

The latest report is now available for a limited time.

Download the free report today.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.

*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

GSK plc (NYSE: GSK) has agreed to acquire full global rights to a trispecific T-cell engager from Chimagen Biosciences in a deal worth up to $750 million. The experimental multiple myeloma therapy is expected to enter Phase I trials in 2027.

The move fits a broader strategy. GSK is buying external oncology programs as it expands its cancer franchise ahead of future patent losses on major HIV medicines.

Another Piece Enters the Oncology Pipeline

GSK will pay an upfront fee, with milestone payments if the program advances. The therapy targets T cells and two tumor antigens, aiming for stronger effectiveness with better tolerability.

The deal matters more once you place it beside GSK’s wider oncology buildout. Earlier this year, the company bought Nuvalent for $10.6 billion, while another Chimagen program is already in Phase I development.

The Market Could Be Much Bigger

GSK estimates the U.S. market for multiple myeloma T-cell engagers could exceed $10 billion by 2032. Successful drugs could carry meaningful commercial value, although clinical risk remains high.

If blood cancer sits within your view of GSK’s future growth, this transaction adds another possible product without requiring the company to build the technology internally.

The agreement follows GSK’s earlier Chimagen partnership and reinforces management’s willingness to buy promising assets that fit established therapeutic areas. That can broaden the pipeline faster than internal research alone.

GSK currently trades at $50.00 and pays a dividend of $1.79 per share, a yield of 3.57%.

Citigroup Inc. (NYSE: C) plans to increase share buybacks beyond the $13 billion repurchased in 2025 while accelerating about $500 million of investment before year-end.

Spending will cover additional restructuring and growth initiatives in credit cards and wealth management.

The change comes after years of simplifying the bank, exiting businesses, and cutting costs. Management now expects return on tangible common equity to move slightly above 11% this year, suggesting the restructuring is beginning to produce better economics.

The Cleanup Is Entering a New Phase

Part of the $500 million will fund severance as Citi continues reducing headcount. At the same time, management is directing more money toward businesses capable of producing stronger growth and returns.

As you separate those two uses of capital, the strategy becomes clearer. Citi is still removing costs, but it is increasingly pairing those cuts with investment rather than treating restructuring as the entire story.

More Capital Can Come Back

Banamex is expected to leave Citi’s balance sheet in 2027, removing another major piece of the old structure. Management also remains open to smaller acquisitions that complement existing businesses rather than transformative deals.

If returns keep improving, you can connect larger buybacks with something more substantial than excess cash. Citi may finally be reaching the point where simplification, targeted growth spending, and capital returns reinforce each other.

C currently trades at $134 and pays a dividend of $2.68 per share, a yield of 1.99%.

In 1971, one Sunday-night announcement changed the dollar almost overnight.

Today, investors are again asking what inflation, policy shifts, and rising central-bank gold demand could mean for retirement savings.

This free guide explains why gold is back in focus, how physical gold can fit into certain retirement strategies, and what some investors are doing to prepare before the next major monetary shift.

See how investors are positioning retirement savings for the next gold move.

*Reagan Gold Group does not provide financial, legal, or tax advice. This information is for educational purposes only and should not be considered investment advice. All investments carry risk, including loss of principal. Past performance is not indicative of future results. Consult your licensed financial advisor before making investment decisions.

The Coca-Cola Company (NYSE: KO) plans to invest $10 billion in U.S. infrastructure between 2026 and 2030, putting substantial new capital behind production and distribution in one of its largest markets.

The company has not yet detailed exactly how the money will be divided.

The size of the commitment matters more than any single factory project. Coca-Cola is preparing the physical system behind its brands for another several years of demand rather than relying only on existing plants and bottling capacity.

Scale Can Protect the Core Business

The U.S. remains one of Coca-Cola’s most important markets, making reliability especially valuable. Infrastructure spending can also support new package sizes, product categories, and changes in where consumers buy beverages.

The $10 billion figure tells you that management is treating domestic capacity as a long-term competitive asset. Distribution reach becomes harder for smaller rivals to match when an already enormous network keeps receiving fresh investment.

The Payoff Comes Over Years

Unlike an acquisition, this spending will not transform Coca-Cola overnight. Returns should appear gradually through capacity, efficiency, supply reliability, and the ability to support future volume.

If you follow where Coca-Cola commits long-duration capital, the U.S. clearly remains central to its plans. The real test is whether those billions translate into stronger operations and durable cash generation through 2030.

KO currently trades at $88 and pays a dividend of $2.12 per share, a yield of 2.40%.

USB raised its quarterly dividend 3.8% to $0.54, its sixth hike in five years, payable October 15 to shareholders of record September 30.

NJR lifted its quarterly payout to $0.50 from $0.475, extending its streak to 31 straight years, payable October 1 to shareholders of record September 24.

TGT boosted its quarterly dividend 1.8% to $1.16, marking its 54th consecutive annual raise.

TNET declared a $0.29 quarterly dividend, payable October 26 to shareholders of record October 1.

CPB cut its quarterly dividend by more than a third, announced alongside fiscal Q4 results on September 3.

ENGI slashed its quarterly payout by two-thirds to 10 cents, pushing the yield from roughly 10% down to about 3.7%.

PLZL flagged plans to suspend dividend payments entirely until 2030 as it prioritizes capital projects.

In the biggest federal push since the Apollo program that landed on the Moon...

Trump is now pouring the full support of the federal government into a new type of AI that could soon be worth 500 times more than ChatGPT.

It works 10,000 times faster than human PhDs... and Elon Musk calls the underlying tech "the most disruptive force in history."

Click here to learn about the #1 stock to own as this new AI goes live.

*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.